UBS lifts Regeneron stock target to USD 978.00

Published on 10/16/2026 at 15:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Regeneron reports third-quarter results on October 30, 2026. Regeneron stock costs EUR 713.20 at Lang & Schwarz during trading on October 16, 2026.

Analyst target and reporting date

UBS upgraded Regeneron from Neutral to Buy and raised its target to USD 978.00 on October 15, 2026.
Regeneron will publish third-quarter 2026 results on October 30, 2026.
Regeneron stock costs EUR 713.20 at Lang & Schwarz on October 16, 2026 at 3:35 p.m. CEST.
Regeneron had a market capitalization of USD 82.0 billion and a P/E ratio of 19.85 on October 16, 2026.

Isometrische 3D-Illustration einer Bioreaktor- und Zellkultur-Prozesskette in Pastellfarben — Regeneron Pharma US75886F1075 stellt ein isometrisches 3D-Diagramm der Bioreaktor-Wertschöpfungskette samt Zellkultur und Aufreinigung dar, Illustration mit AI erstellt.

UBS upgraded Regeneron from Neutral to Buy and raised its price target from USD 660.00 to USD 978.00 in a research report dated October 15, 2026, according to MarketBeat. Against Regeneron's USD 796.82 Nasdaq price on October 16, 2026, the new target stands 22.76 percent higher.

UBS target resets the valuation frame

The analyst action gives the stock a clear numerical reference ahead of the next results date. MarketBeat also listed a consensus target of USD 845.21 on October 15, 2026, while its report identified long-term growth potential for Dupixent as UBS's central argument.

The target change was substantial: UBS moved from USD 660.00 to USD 978.00, an increase of 48.18 percent. The rating also moved from Neutral to Buy, giving investors two separate signals to compare with the current quotation.

Price position and trading range

At Lang & Schwarz, Regeneron stock was trading at EUR 713.20 on October 16, 2026 at 3:35 p.m. CEST. The bid was EUR 711.50 and the ask was EUR 714.90. The quotation was in Xetra trading hours.

The primary Nasdaq quotation was USD 796.82 at 1:45 p.m. ET on October 16, 2026. Regeneron's 52-week Nasdaq range was USD 566.11 to USD 859.34, placing the price USD 62.52 below the high and USD 230.71 above the low.

Valuation and the next date

Regeneron's market capitalization was USD 82.0 billion and its P/E ratio was 19.85 on October 16, 2026. The company had no trailing dividend yield in the quoted data.

Regeneron will report third-quarter 2026 financial and operating results before the U.S. market opens on October 30, 2026, and will host its conference call at 8:30 a.m. ET, according to Regeneron.

Comparison with peers

Regeneron: P/E 19.85, market capitalization USD 82.0 billion

Eli Lilly and Company (NYSE, USD): P/E 42.25, dividend yield 0.01 percent, market capitalization USD 1.2 trillion

GSK plc (NYSE, USD): P/E 15.71, dividend yield 0.04 percent, market capitalization USD 99.5 billion

What the figures leave open

The market now has a fresh UBS target and a fixed reporting date to weigh against Regeneron's valuation. The next material test is whether the third-quarter numbers support the expectations embedded in the USD 978.00 target.

Regeneron stock was trading at EUR 713.20 at Lang & Schwarz on October 16, 2026 at 3:35 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Regeneron stock.